2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Autor: 2seventy bio, Inc.
Zdroj: Business Wire (English). 05/11/2023.
Abstrakt: 2seventy bio, Inc. (Nasdaq: TSVT) today announced the presentation of four abstracts at theAmerican Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 2-6, 2023 in Chicago, Illinois and six abstracts at the European Hematology Association (EHA) Congress, taking place in Frankfurt, Germany from June 8-11, 2023. [ABSTRACT FROM PUBLISHER]
Databáze: Regional Business News
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje